Cargando…
The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion
BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578478/ https://www.ncbi.nlm.nih.gov/pubmed/28551353 http://dx.doi.org/10.1016/j.healun.2017.05.012 |
_version_ | 1783260537130319872 |
---|---|
author | Andreasson, Anders S.I. Borthwick, Lee A. Gillespie, Colin Jiwa, Kasim Scott, Jonathan Henderson, Paul Mayes, Jonny Romano, Rosalba Roman, Marius Ali, Simi Fildes, James E. Marczin, Nandor Dark, John H. Fisher, Andrew J. |
author_facet | Andreasson, Anders S.I. Borthwick, Lee A. Gillespie, Colin Jiwa, Kasim Scott, Jonathan Henderson, Paul Mayes, Jonny Romano, Rosalba Roman, Marius Ali, Simi Fildes, James E. Marczin, Nandor Dark, John H. Fisher, Andrew J. |
author_sort | Andreasson, Anders S.I. |
collection | PubMed |
description | BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This study assessed the predictive value of markers of inflammation and tissue injury in donor lungs undergoing EVLP as part of the DEVELOP-UK study. METHODS: Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates from EVLP assessments was investigated on a microfluidic platform. RESULTS: The most effective markers to differentiate between in-hospital survival and non-survival post-transplant were perfusate interleukin (IL)-1β (area under the curve = 1.00, p = 0.002) and tumor necrosis factor-α (area under the curve = 0.95, p = 0.006) after 30 minutes of EVLP. IL-1β levels in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature (R(2) = 0.68, p < 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1 (R(2) = 0.30, p = 0.001) and E-selectin (R(2) = 0.29, p = 0.001) in conditioned HPMECs and neutrophil adhesion to conditioned HPMECs (R(2) = 0.33, p < 0.001). Neutralization of IL-1β in perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction, p = 0.002). CONCLUSIONS: Donor lungs develop a detectable and discriminatory pro-inflammatory signature in perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo. |
format | Online Article Text |
id | pubmed-5578478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55784782017-09-06 The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion Andreasson, Anders S.I. Borthwick, Lee A. Gillespie, Colin Jiwa, Kasim Scott, Jonathan Henderson, Paul Mayes, Jonny Romano, Rosalba Roman, Marius Ali, Simi Fildes, James E. Marczin, Nandor Dark, John H. Fisher, Andrew J. J Heart Lung Transplant Article BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can be successfully reconditioned and will function well post-operatively has not been established. This study assessed the predictive value of markers of inflammation and tissue injury in donor lungs undergoing EVLP as part of the DEVELOP-UK study. METHODS: Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates from EVLP assessments was investigated on a microfluidic platform. RESULTS: The most effective markers to differentiate between in-hospital survival and non-survival post-transplant were perfusate interleukin (IL)-1β (area under the curve = 1.00, p = 0.002) and tumor necrosis factor-α (area under the curve = 0.95, p = 0.006) after 30 minutes of EVLP. IL-1β levels in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature (R(2) = 0.68, p < 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1 (R(2) = 0.30, p = 0.001) and E-selectin (R(2) = 0.29, p = 0.001) in conditioned HPMECs and neutrophil adhesion to conditioned HPMECs (R(2) = 0.33, p < 0.001). Neutralization of IL-1β in perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction, p = 0.002). CONCLUSIONS: Donor lungs develop a detectable and discriminatory pro-inflammatory signature in perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo. Elsevier 2017-09 /pmc/articles/PMC5578478/ /pubmed/28551353 http://dx.doi.org/10.1016/j.healun.2017.05.012 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Andreasson, Anders S.I. Borthwick, Lee A. Gillespie, Colin Jiwa, Kasim Scott, Jonathan Henderson, Paul Mayes, Jonny Romano, Rosalba Roman, Marius Ali, Simi Fildes, James E. Marczin, Nandor Dark, John H. Fisher, Andrew J. The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title | The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title_full | The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title_fullStr | The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title_full_unstemmed | The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title_short | The role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
title_sort | role of interleukin-1β as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578478/ https://www.ncbi.nlm.nih.gov/pubmed/28551353 http://dx.doi.org/10.1016/j.healun.2017.05.012 |
work_keys_str_mv | AT andreassonanderssi theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT borthwickleea theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT gillespiecolin theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT jiwakasim theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT scottjonathan theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT hendersonpaul theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT mayesjonny theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT romanorosalba theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT romanmarius theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT alisimi theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT fildesjamese theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT marczinnandor theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT darkjohnh theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT fisherandrewj theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT theroleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT andreassonanderssi roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT borthwickleea roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT gillespiecolin roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT jiwakasim roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT scottjonathan roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT hendersonpaul roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT mayesjonny roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT romanorosalba roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT romanmarius roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT alisimi roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT fildesjamese roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT marczinnandor roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT darkjohnh roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT fisherandrewj roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion AT roleofinterleukin1basapredictivebiomarkerandpotentialtherapeutictargetduringclinicalexvivolungperfusion |